Strategic collaborations OSE Immunotherapeutics has established and pursued multiple co-development agreements with Veloxis (transplant focus) and AbbVie (ChemR23 agonist for chronic inflammation) as well as ongoing partnerships with Boehringer Ingelheim. These relationships indicate a strong channel for collaboration and potential for joint opportunities in IO, I&I, and transplant-related indications.

R&D pipeline strength A diversified portfolio across immuno-oncology and immuno-inflammation, including Tedopi in Phase 3 for second-line NSCLC, OSE-279 in solid tumors, FR-104/VEL-101 in transplantation, and anti-SIRPα programs. This breadth offers multiple near-term selling moments as trials progress and potential expansion into comparator or combination therapies.

Clinical milestones Recent topline results and ongoing Phase 2/Phase 3 readouts (Tedopi in ovarian cancer, OSE-279 Phase 1/2 signals, and SIRPα Phase 2 planning) provide clear inflection points for partner discussions, licensing, or co-development deals timed around milestone events.

Strategic leadership New leadership appointments, including a permanent CEO and a newly appointed Deputy CEO, signal a renewed growth strategy and readiness to scale partnerships, marketing of assets, and global business development efforts.

Financial and visibility signals With a modest revenue band and $86M in funding, there is appetite for external partnerships and licensing deals to accelerate late-stage development and global commercialization, particularly leveraging AbbVie and Boehringer Ingelheim collaborations to access larger markets.